Cargando…

Combination of metronomic cyclophosphamide and dietary intervention inhibits neuroblastoma growth in a CD1-nu mouse model

BACKGROUND: MYCN-amplification in high-grade Neuroblastoma (NB) tumors correlates with increased vascularization and therapy resistance. This study combines an anti-angiogenic approach with targeting NB metabolism for treatment. METHODS AND RESULTS: Metronomic cyclophosphamide (MCP) monotherapy sign...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morscher, Raphael Johannes, Aminzadeh-Gohari, Sepideh, Hauser-Kronberger, Cornelia, Feichtinger, René Günther, Sperl, Wolfgang, Kofler, Barbara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941371/ https://www.ncbi.nlm.nih.gov/pubmed/26959744 http://dx.doi.org/10.18632/oncotarget.7929

Ejemplares similares

Inhibition of Neuroblastoma Tumor Growth by Ketogenic Diet and/or Calorie Restriction in a CD1-Nu Mouse Model
por: Morscher, Raphael Johannes, et al.
Publicado: (2015)

Triple Therapy with Metformin, Ketogenic Diet, and Metronomic Cyclophosphamide Reduced Tumor Growth in MYCN-Amplified Neuroblastoma Xenografts
por: Catalano, Luca, et al.
Publicado: (2023)

A ketogenic diet supplemented with medium-chain triglycerides enhances the anti-tumor and anti-angiogenic efficacy of chemotherapy on neuroblastoma xenografts in a CD1-nu mouse model
por: Aminzadeh-Gohari, Sepideh, et al.
Publicado: (2017)

Low aerobic mitochondrial energy metabolism in poorly- or undifferentiated neuroblastoma
por: Feichtinger, Rene' G, et al.
Publicado: (2010)

The ketogenic diet is not feasible as a therapy in a CD-1 nu/nu mouse model of renal cell carcinoma with features of Stauffer's syndrome
por: Vidali, Silvia, et al.
Publicado: (2017)

Lithium and Not Acetoacetate Influences the Growth of Cells Treated with Lithium Acetoacetate
por: Vidali, Silvia, et al.
Publicado: (2019)

Targeting Mitochondria in Melanoma
por: Aminzadeh-Gohari, Sepideh, et al.
Publicado: (2020)

From old to new — Repurposing drugs to target mitochondrial energy metabolism in cancer
por: Aminzadeh-Gohari, Sepideh, et al.
Publicado: (2020)

Ketogenic diet in the treatment of cancer – Where do we stand?
por: Weber, Daniela D., et al.
Publicado: (2019)

Verteporfin-induced proteotoxicity impairs cell homeostasis and survival in neuroblastoma subtypes independent of YAP/TAZ expression
por: Condurat, Alexandra-Larisa, et al.
Publicado: (2023)

Acrolein: unwanted side product or contribution to antiangiogenic properties of metronomic cyclophosphamide therapy?
por: Günther, M, et al.
Publicado: (2008)

Untargeted Metabolomics Reveals Molecular Effects of Ketogenic Diet on Healthy and Tumor Xenograft Mouse Models
por: Licha, David, et al.
Publicado: (2019)

Metabolic reprogramming related to whole-chromosome instability in models for Hürthle cell carcinoma
por: Addie, Ruben D., et al.
Publicado: (2020)

Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
por: Dickinson, P D, et al.
Publicado: (2012)

Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
por: Pujade-Lauraine, Eric
Publicado: (2013)

Targeted Metabolomics Identifies Plasma Biomarkers in Mice with Metabolically Heterogeneous Melanoma Xenografts
por: Weber, Daniela D., et al.
Publicado: (2021)

Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
por: Khan, O A, et al.
Publicado: (2012)

Metastatic Primary Duodenal Adeno-Carcinoma Responding to Metronomic Oral Cyclophosphamide Chemotherapy
por: Bandyopadhyay, Anis, et al.
Publicado: (2014)

Metronomic cyclophosphamide with bevacizumab provides disease stabilization in patients with advanced uterine cancer
por: Alagkiozidis, Ioannis, et al.
Publicado: (2015)

Metronomic chemotherapy with cyclophosphamide for the treatment of advanced hepatocellular cancer: A case report
por: Peristeri, Dimitra V., et al.
Publicado: (2021)

The Switch in the Diagnosis of Mitochondrial Diseases from the Classical ‘Function First’ To the NGS-based ‘Genetics First’ Diagnostic Era
por: Sperl, Wolfgang, et al.
Publicado: (2020)

VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment
por: Patten, Steven G, et al.
Publicado: (2010)

A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer
por: Kelley, R K, et al.
Publicado: (2013)

Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models
por: Mainetti, Leandro E., et al.
Publicado: (2020)

Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer
por: Samaritani, Riccardo, et al.
Publicado: (2007)

Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
por: Orlando, Laura, et al.
Publicado: (2006)

Bevacizumab with metronomic chemotherapy of low-dose oral cyclophosphamide in recurrent cervical cancer: Four cases
por: Isono-Nakata, Rose, et al.
Publicado: (2018)

Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion
por: Muñoz, Raquel, et al.
Publicado: (2019)

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2023)

Urinary bladder hemangiosarcoma in a cat treated with partial cystectomy and adjuvant metronomic cyclophosphamide and thalidomide
por: McNally, Abigail, et al.
Publicado: (2023)

Age-Related Deterioration of Mitochondrial Function in the Intestine
por: Schneider, Anna M., et al.
Publicado: (2020)

Ketogenic diets slow melanoma growth in vivo regardless of tumor genetics and metabolic plasticity
por: Weber, Daniela D., et al.
Publicado: (2022)

The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
por: Barber, Emma L., et al.
Publicado: (2013)

Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer
por: Bazzola, L, et al.
Publicado: (2015)

Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer
por: Khan, Kabir A., et al.
Publicado: (2020)

Effectiveness and toxicity of metronomic oral cyclophosphamide for recurrent or platinum-refractory ovarian cancer: A meta-analysis
por: Huang, Lili, et al.
Publicado: (2022)

Oxidative Phosphorylation System in Gastric Carcinomas and Gastritis
por: Feichtinger, René G., et al.
Publicado: (2017)

Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care
por: Penel, N, et al.
Publicado: (2010)

Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
por: Allegrini, Giacomo, et al.
Publicado: (2012)

Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer
por: Soriano, Jorge L., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_srj1r8pq94tiidfs8kut4gq3ra